How to transfer my Wegovy prescription to Texas

If you’ve been considering medications like Wegovy, Ozempic, or Mounjaro for weight loss, you’ve probably wondered: Can I actually get these prescribed through telehealth? The short answer is yes—and for many people, telehealth has become the most convenient and accessible way to start treatment.

With obesity affecting over 40% of American adults and groundbreaking GLP-1 medications now available, telehealth has transformed how we access weight management care. But navigating the rules—federal regulations, state-specific requirements, and provider qualifications—can feel overwhelming.

In this guide, we’ll walk you through everything you need to know about getting weight loss medication through telehealth in 2025, including what’s legal, what to expect, and how to find safe, legitimate care.

The Legal Landscape: Federal Rules Make Telehealth Weight Loss Prescriptions Possible

Here’s the good news: Federal law does not require an in-person visit before prescribing GLP-1 weight loss medications like Wegovy, Ozempic, or Mounjaro through telehealth.

Unlike controlled substances (such as Adderall or opioids), which fall under the stricter Ryan Haight Act requiring in-person exams, GLP-1 medications are not controlled substances. This means healthcare providers can legally prescribe them after establishing a valid patient-provider relationship via live video consultation in most cases.

Current Federal Status (As of December 2025)

The Drug Enforcement Administration (DEA) extended COVID-era telehealth flexibilities through December 31, 2025, but these primarily affect controlled medications. For non-controlled drugs like semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro), there has never been a federal in-person requirement.

What providers do need to establish:

• A legitimate patient-provider relationship (typically through live video)
• A thorough medical evaluation and history
• Appropriate documentation and informed consent
• A treatment plan that includes lifestyle modifications
• Regular follow-up and monitoring

At Klarity Health, our licensed providers follow all federal and state regulations to ensure you receive safe, compliant care—whether you’re starting treatment or continuing ongoing weight management.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-by-State Variations: Understanding Your Local Requirements

While federal law broadly permits telehealth prescribing of weight loss medications, individual states can impose additional requirements. Some states require initial in-person exams, periodic check-ins, or specific documentation.

States Requiring Initial In-Person Exams

Several states mandate that patients have at least one in-person physical examination before or shortly after starting telehealth weight loss treatment:

• Arkansas: Initial exam must be in-person; among the most restrictive telehealth states
• Delaware: First physical exam required in-person before tele-prescribing
• Georgia: In-person exam required prior to telehealth prescriptions
• Mississippi: Initial in-person evaluation mandated for weight management
• New Jersey: Comprehensive in-person exam with lab work required at start
• North Dakota: Hands-on initial evaluation expected
• South Carolina: First examination must be completed in person
• Texas: In-person exam generally expected before telehealth prescribing
• Virginia: Initial physical exam and lab tests required, plus 30-day follow-up

States With Full Telehealth Access (No In-Person Requirement)

Many states allow complete telehealth-based weight loss treatment from start to finish:

• California: Telehealth exam is sufficient; no in-person mandate
• Connecticut: Requires behavioral counseling and lifestyle plan, but no in-person visit
• Illinois: No special in-person requirements
• New York: Telehealth exam satisfies requirements
• Pennsylvania: No in-person mandate for weight loss medications
• Washington: Fully permitted via telehealth with no restrictions

States With Ongoing Monitoring Requirements

Some states don’t require initial in-person visits but mandate regular follow-ups:

• Florida: Patients must have BMI ≥30 and be seen at least every 3 months during treatment
• Virginia: Requires follow-up within 30 days of starting therapy

The good news? Klarity Health operates in multiple states and ensures our providers are fully licensed and compliant with each state’s unique requirements. We’ll guide you through what’s needed in your specific location.

Who Can Prescribe Weight Loss Medications via Telehealth?

Physicians (MDs and DOs)

All states allow licensed physicians to prescribe GLP-1 weight loss medications through telehealth, provided they’re licensed in the state where you’re located during the consultation.

Nurse Practitioners (NPs) and Physician Assistants (PAs)

The ability of NPs and PAs to prescribe varies significantly by state:

Full Independent Practice (34+ states): NPs can prescribe without physician oversight in states like:

• California (after 3+ years experience)
• New York (after 3,600 supervised hours)
• Washington
• Arizona
• Connecticut
• Utah

Collaborative Practice Required: States like Texas, Florida, and Pennsylvania require NPs and PAs to work under physician agreements or supervision.

Recent Expansions: Georgia passed legislation in 2024 allowing NPs and PAs to prescribe Schedule II controlled substances with physician delegation—a significant step toward broader prescribing authority.

At Klarity Health, we work with appropriately credentialed MDs, DOs, NPs, and PAs who are licensed and authorized to prescribe in your state. You’ll receive the same high standard of care regardless of your provider’s credential type.

What Medications Can Be Prescribed Through Telehealth?

Wegovy (Semaglutide 2.4mg)

• FDA-approved specifically for chronic weight management
• Eligibility: BMI ≥30 or ≥27 with weight-related comorbidities
• Federal status: Unscheduled (not a controlled substance)
• Telehealth: Fully permitted in most states
• Important note: FDA ended emergency allowances for compounded semaglutide in May 2025—only FDA-approved versions should be prescribed

Ozempic (Semaglutide 0.5-1mg)

• FDA-approved for Type 2 diabetes
• Off-label use for weight loss is common and legal
• Requirements: Providers must document off-label rationale and obtain informed consent
• Same active ingredient as Wegovy; should not be combined with other semaglutide products

Mounjaro/Zepbound (Tirzepatide)

• Mounjaro: FDA-approved for Type 2 diabetes
• Zepbound: FDA-approved specifically for obesity (launched late 2023)
• Telehealth prescribing: Legal for weight loss when criteria are met
• Requires patient training on self-injection technique

All three medications are non-controlled and can be prescribed via telehealth under federal law. They typically come in pre-filled injection pens and require proper storage and handling instructions.

The Telehealth Consultation Process: What to Expect

1. Initial Assessment

Your telehealth weight loss journey typically begins with:

• Detailed medical questionnaire: Current medications, allergies, medical history
• Height and weight verification: To calculate BMI
• Health screening: Identifying contraindications like thyroid cancer history, pregnancy plans, or active gallbladder disease
• Lifestyle assessment: Current diet, exercise habits, previous weight loss attempts

2. Live Video Consultation

A licensed provider will:

• Review your medical history and weight loss goals
• Discuss how GLP-1 medications work and set realistic expectations
• Explain common side effects (nausea, GI upset, injection site reactions)
• Screen for contraindications and drug interactions
• Create a personalized treatment plan including diet and exercise recommendations
• Obtain informed consent

3. Prescription and Medication Delivery

If appropriate:

• Electronic prescription sent directly to your pharmacy (or a mail-order pharmacy)
• Initial prescriptions typically for 4 weeks to assess tolerance
• Instructions provided for injection technique and storage
• Most GLP-1s require refrigeration until first use

4. Ongoing Monitoring

Legitimate telehealth services include:

• Regular follow-ups: Usually 1 month after starting, then every 2-3 months
• Weight and side effect tracking: Monitoring progress and adjusting dose as needed
• Lab work: Periodic metabolic panels or A1C tests may be recommended
• Lifestyle coaching: Continued support for diet and exercise modifications

Klarity Health builds this comprehensive monitoring into our program, with transparent pricing and flexible scheduling—because weight management is a journey, not a one-time prescription.

Safety Considerations: What Makes Telehealth Weight Loss Legitimate

Red Flags to Avoid

Be cautious of telehealth services that:

1. Guarantee prescriptions without evaluation: Any service promising medication before assessing your health is unsafe
2. Skip live consultations: Questionnaire-only services without provider interaction cut corners
3. Offer compounded or overseas versions: The FDA banned most compounded semaglutide in 2025 due to safety concerns
4. Lack transparent pricing: Hidden fees or unclear costs suggest questionable practices
5. Don’t schedule follow-ups: Ongoing monitoring is essential for safety and effectiveness
6. Aren’t transparent about licensing: Providers must be licensed in your state

What Legitimate Services Provide

High-quality telehealth weight loss programs include:

• Licensed, credentialed providers in your state
• Comprehensive medical screening before prescribing
• Informed consent discussion covering risks and alternatives
• FDA-approved medications only (not compounded versions)
• Regular monitoring and follow-up visits
• Integration with lifestyle modifications (diet, exercise, behavioral support)
• Clear documentation in your medical record
• Transparent pricing with no hidden fees

Klarity Health checks all these boxes. We accept both insurance and offer transparent cash-pay options, making quality care accessible whether you have coverage or not.

Clinical Eligibility: Who Qualifies for GLP-1 Weight Loss Medications?

Standard Criteria

FDA-approved indications for weight loss medications include:

Primary qualification:

• BMI ≥30 (obesity), OR
• BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, high cholesterol, sleep apnea)

Additional considerations:

• Age 18 or older (in most cases)
• Previous attempts at lifestyle modification (diet and exercise)
• Commitment to ongoing lifestyle changes alongside medication
• No contraindications present

Common Contraindications

You may not be eligible if you have:

• Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy or plans to become pregnant (must discontinue 2 months before conception)
• Active pancreatitis or history of severe pancreatitis
• Severe gastrointestinal disorders (gastroparesis, inflammatory bowel disease)
• Active gallbladder disease
• History of severe allergic reactions to semaglutide or tirzepatide
• Eating disorders (bulimia, anorexia nervosa)

Realistic Expectations

Reputable telehealth providers will counsel you that:

• GLP-1 medications are not quick fixes—results take months
• Average weight loss is 10-15% of body weight over 6-12 months
• Medications work best combined with lifestyle changes
• Side effects are common initially but often improve
• Treatment may be long-term or indefinite for maintaining results
• Not everyone responds equally to these medications

Cost and Insurance Coverage

Insurance Coverage

Many insurance plans now cover FDA-approved weight loss medications:

• Medicare Part D: Some plans cover Wegovy as of 2023
• Commercial insurance: Coverage varies widely; many plans require prior authorization
• Medicaid: State-dependent; some states cover obesity medications

Klarity Health works with your insurance to maximize coverage and handles prior authorization paperwork when needed.

Cash-Pay Options

For those without coverage:

• Wegovy: $1,300-$1,500/month (retail)
• Ozempic (off-label): $900-$1,000/month
• Mounjaro/Zepbound: $1,000-$1,200/month

Manufacturer savings programs and discount cards can significantly reduce out-of-pocket costs—sometimes to $25-$550/month depending on eligibility.

Klarity Health offers transparent cash-pay pricing with no hidden fees, and our team helps you access available savings programs.

The Future of Telehealth Weight Loss Care

Regulatory Outlook

The trajectory is clear: telehealth is here to stay for weight management.

Expected developments:

• DEA’s temporary telehealth rules for controlled substances will likely be extended beyond 2025 (or new permanent rules established)
• More states are adopting full practice authority for NPs, expanding provider availability
• Congress is considering the TREATS Act to permanently allow some telehealth prescribing without in-person requirements
• Interstate licensing compacts continue to expand, making multi-state practice easier

Technology and Access Improvements

Emerging trends include:

• Integrated monitoring: Smart scales and apps syncing with telehealth platforms
• AI-assisted coaching: Personalized diet and exercise recommendations
• Expanded medication options: New GLP-1 formulations and combinations in development
• Lower costs: As competition increases and patents expire, prices should decrease

Privacy Protections

States like Washington enacted consumer health data privacy laws (My Health My Data Act, 2023) specifically addressing telehealth. Legitimate providers must ensure:

• HIPAA compliance for all health information
• Secure video platforms
• Protected health data sharing with pharmacies
• Informed consent for data use

Klarity Health maintains strict HIPAA compliance and uses encrypted, secure platforms for all consultations and communications.

Why Choose Klarity Health for Telehealth Weight Loss?

At Klarity Health, we’ve built our weight management program around what matters most: accessibility, safety, and personalized care.

What Sets Us Apart

✓ Licensed providers in your state: We ensure compliance with all federal and state regulations

✓ Comprehensive evaluation: Thorough medical screening and ongoing monitoring—not just prescription mills

✓ Transparent pricing: Clear costs upfront, whether you’re using insurance or cash pay

✓ Insurance accepted: We work with most major insurance plans and handle prior authorizations

✓ Flexible scheduling: Convenient video appointments that fit your life

✓ Ongoing support: Regular follow-ups and access to your care team throughout your journey

✓ Lifestyle integration: Evidence-based guidance on diet, exercise, and behavioral changes

✓ FDA-approved medications only: We prescribe only genuine, FDA-approved medications from licensed U.S. pharmacies

Frequently Asked Questions

Q: Do I need to have an in-person visit before getting weight loss medication through telehealth?

A: It depends on your state. Many states allow completely virtual care from start to finish (California, New York, Pennsylvania, Washington), while others require an initial in-person exam (Texas, Georgia, New Jersey, Arkansas). Klarity Health will guide you through your state’s specific requirements.

Q: Are GLP-1 weight loss medications controlled substances?

A: No. Wegovy, Ozempic, and Mounjaro/Zepbound are not controlled substances, which is why they can be prescribed via telehealth without the strict federal requirements that apply to medications like Adderall.

Q: Can nurse practitioners prescribe these medications?

A: Yes, in all 50 states NPs can prescribe GLP-1 medications, though the level of independence varies. In states with full practice authority (34+ states), NPs can prescribe independently. In others, they work under physician collaboration. All Klarity Health NPs are properly authorized to prescribe in your state.

Q: What about compounded semaglutide I see advertised online?

A: Be cautious. The FDA banned routine compounding of semaglutide for weight loss in May 2025 after declaring the shortage over. Legitimate telehealth providers like Klarity Health prescribe only FDA-approved versions from licensed pharmacies.

Q: How long do I need to take these medications?

A: GLP-1 medications are typically long-term treatments. Most people regain weight if they stop, so treatment may continue indefinitely as long as it’s safe and effective. Your provider will discuss the best approach for your individual situation.

Q: Will my insurance cover telehealth weight loss consultations?

A: Many insurance plans now cover telehealth visits at the same rate as in-person visits. Coverage for the medications themselves varies. Klarity Health accepts most major insurance plans and can verify your coverage before your appointment.

Q: What happens if I move to a different state during treatment?

A: Telehealth providers must be licensed in the state where you’re physically located during treatment. If you move, you’ll need to connect with a provider licensed in your new state. Klarity Health operates in multiple states and can often facilitate your continued care.

Q: Are there any age restrictions?

A: Wegovy is FDA-approved for adults and adolescents aged 12+ with obesity. Ozempic and Mounjaro are approved for adults 18+. Telehealth prescribing for minors may have additional requirements depending on state law.

Take the First Step Toward Your Weight Loss Goals

The combination of breakthrough GLP-1 medications and convenient telehealth access has transformed weight management. For many people struggling with obesity, effective treatment is now more accessible than ever—often from the comfort of home.

If you’re ready to explore whether weight loss medication is right for you, Klarity Health makes it simple:

1. Complete a brief online assessment (5-10 minutes)
2. Schedule a video consultation with a licensed provider in your state
3. Get personalized care with ongoing support throughout your journey

We accept insurance and offer transparent cash-pay pricing. No hidden fees, no pressure—just honest, evidence-based care to help you reach your goals safely.

Ready to get started? Visit Klarity Health today to schedule your consultation and take the first step toward sustainable weight loss.

References and Sources

This article was researched and fact-checked using current federal regulations, state medical board guidelines, and clinical sources as of December 17, 2025.

Top 5 Key Citations:

1. DEA and HHS Extend Telemedicine Flexibilities through 2025 – U.S. Drug Enforcement Administration, November 15, 2024. www.dea.gov

2. COVID-era telehealth prescribing extended – Axios, November 18, 2024. www.axios.com

3. The Changing Regulatory and Reimbursement Landscape for Weight Loss Drugs – Goodwin Procter LLP, March 27, 2024. www.goodwinlaw.com

4. DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025 – McDermott Will & Emery, November 18, 2024. www.mwe.com

5. Hims & Hers to cut 4% of workforce amid ban on weight-loss drug copies – Reuters, May 30, 2025. www.reuters.com

Additional state-specific regulations were verified through official state medical board websites, statutes, and regulatory guidance documents. All information current as of December 17, 2025.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any weight loss treatment. Individual results may vary. GLP-1 medications may not be appropriate for everyone and carry risks including potential side effects. Klarity Health providers will evaluate your individual circumstances to determine the most appropriate treatment approach.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid